Showing 13 of 13 recruiting trials for “Indolent B-cell non-Hodgkin lymphoma”
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
👨⚕️ Sumithira Vasu, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Feb 2026View details ↗
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
👨⚕️ Alexandre V. Hirayama, MD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Dec 2025View details ↗
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
👨⚕️ Narendranath Epperla, MD, MS, FACP, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Sep 2025View details ↗
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
👨⚕️ Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Aug 2025View details ↗
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
👨⚕️ Brandon Imber, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Jun 2025View details ↗
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
👨⚕️ Elise Chong, MD, Abramson Cancer Center at the University of Pennsylvania📍 1 site📅 Started Sep 2024View details ↗
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
👨⚕️ Ajay Gopal, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Aug 2024View details ↗
Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
👨⚕️ Nathan Denlinger, DO, MS, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Jan 2024View details ↗
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →